Econophy Biotech NMMI Diagnostics

The site needs to showcase a first-in-class, safe, non-invasive nuclear medicine and molecular imaging technology designed for the detection and monitoring of pulmonary diseases. It is patented in the US, EU, and Canada. Due to the innovative and expansive capability to create derivative diagnostics, based on the underlying technology functions and capacities, the technology can be refocused on critical need diseases. We have been approached by an Indian-based pharma company to create a TB derivative to address their country's crisis. Another derivative development will focus on Climate Change, specifically the impact of Particulate Matter (PM) on children and adults around the world. This is the WHO report on Particulate Matter (PM) as generated by Climate Change - [login to view URL] In itself, our biotech is an industry disruptive innovation to replace the world standard diagnostic treatment known as the Macroaggregated Albumin (MAA), which has a limitation of 50 microns. Based on successful Phase I & II clinical trials, our efficacy provided to be 5X greater than the MAA capability. In addition to its primary, and multi-faceted functional capabilities, future derivative development will also focus on diseases involving the liver, kidneys, gallbladder, and bladder. Replacing the industry-standard Single Photon Emission Computed Tomography (SPECT) scan with the integration of a Positron Emission Tomography (PET), we are first-movers that can apply the PET to numerous diseases, particularly one primarily impacting women. The prospects for a TB and Particulate Matter diagnostic are spectacular, but there are other conditions that we have been investigating with additional huge potential. These include: SARS (Severe Acute Respiratory Syndrome) Scleroderma Bronchopulmonary Dysplasia COPD (Chronic Obstructive Pulmonary Disorder) Pulmonary Fibrosis There is also the area of pediatric diagnosis. PulmoBind will be of great value here, but particularly in relation to CAT scans. Children are considerably more sensitive to radiation-induced damage than adults. Children also have a longer life expectancy than adults, resulting in a larger window of opportunity for expressing radiation damage. Replacing pediatric pulmonary-related CAT scans with PulmoBind scans would be very beneficial. Our pulmonary, TB and Climate Change derivatives will target these countries: The US. Canada UK & EU India ME Japan South Korea Latin America Qatar Egypt Saudi Arabia and Bahrain We do have an experienced copywriter with a background in B2B, Life Sciences, and Biotech as our adviser. Please see - [login to view URL] In advance, thank you for this consideration. We look forward to receiving your comments and/or suggestions on this project. Kind regards, Michael M. Damian Billy